Summary of use during lactation
Inmazeb is a mixture of monoclonal antibodies, atoltivimab, maftivimab, and odesivimab that are directed against Zaire ebolavirus glycoprotein. No information is available on the use of inmazeb during breastfeeding. Because inmazeb is a mixture of large protein molecules with molecular weights of 144,000 to 146,000 Da, the amount in milk is likely to be very low and absorption is unlikely because the antibodies are probably destroyed in the infant's gastrointestinal tract. Until more data become available, inmazeb should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The US Centers for Disease Control and Prevention recommend that patients with confirmed Zaire ebolavirus not breastfeed their infants to reduce the risk of postnatal transmission of Zaire ebolavirus infection.
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.